Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Vascular endothelial growth factor (VEGF) is an important active protein for the induction of angiogenesis and improvement in cardiac function after myocardial ischemia; however, the lack of a delivery system targeted to the injured myocardium reduces the local therapeutic efficacy of VEGF and increases its possible adverse effects.
|
19307480 |
2009 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Sildenafil-mediated neovascularization and protection against myocardial ischaemia reperfusion injury in rats: role of VEGF/angiopoietin-1.
|
18373738 |
2008 |
Coronary Arteriosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We aimed to investigate the correlation between the levels of circulating miR-214 and the expression of vascular endothelial growth factor (VEGF) in the pathogenesis of coronary heart disease patients to further explore the mechanism involved in the vasculogenesis.
|
25575606 |
2015 |
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We examined two VEGF polymorphisms, including +405 C/G (rs2010963) and -2578C/A (rs699947), to assess their relation to the extent of coronary atherosclerosis.
|
20489684 |
2010 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thymosin beta-4 (TB4) and vascular endothelial growth factor (VEGF) are linked to adult epicardial progenitor cell mobilization and neovascularization and is cardioprotective after myocardial ischemia.
|
21332365 |
2011 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Vascular endothelial growth factor gene transfer therapy for coronary artery disease: A systematic review and meta-analysis.
|
30035366 |
2018 |
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association of Genetic Polymorphisms on Vascular Endothelial Growth Factor and its Receptor Genes with Susceptibility to Coronary Heart Disease.
|
26726843 |
2016 |
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In univariate analysis, all three VEGF polymorphisms (460C, 1154A, and 2578A) were significantly associated with a higher prevalence of coronary artery disease (P < .01) and greater frequencies of hypertension were found in carriers of the 1154A allele and the 2578A allele (P = .01).
|
28364978 |
2017 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Several clinical trials based on intramyocardial injection of VEGF DNA in patients with otherwise inoperable coronary artery disease and intractable angina pectoris have recently been completed.
|
14728030 |
2001 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
PET for evaluation of differential myocardial perfusion dynamics after VEGF gene therapy and laser therapy in end-stage coronary artery disease.
|
15347709 |
2004 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
This report summarizes a phase I clinical experience with a gene-therapy strategy that used an E1(-)E3(-) adenovirus (Ad) gene-transfer vector expressing human vascular endothelial growth factor (VEGF) 121 cDNA (Ad(GV)VEGF121.10) to induce therapeutic angiogenesis in the myocardium of individuals with clinically significant coronary artery disease.
|
10430759 |
1999 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Neovascularization stimulated by VEGF occurs in several important clinical contexts, including myocardial ischemia, retinal disease, and tumor growth.
|
8756616 |
1996 |
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Genotyping for VEGF gene +405 G>C polymorphism was performed in 64 patients with coronary artery disease at a mean age of 66 years (76.6% males), with a mean EuroSCORE (European System for Cardiac Operative Risk Evaluation) of 2.5 (0-2 points: 50% patients, 3-4: 25%, > or =5 points: 25%), who underwent CABG surgery.
|
19920796 |
2009 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Vascular endothelial growth factor and its receptor the kinase domain receptor play critical roles in the pathogenesis of coronary artery disease.
|
21573804 |
2012 |
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Expression profile of total VEGF, VEGF splice variants and VEGF receptors in the myocardium and arterial vasculature of diabetic and non-diabetic patients with coronary artery disease.
|
17961532 |
2008 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Currently, about 200 patients have been treated with intramyocardial VEGF gene therapy for peripheral occlusive artery disease or for myocardial ischemia.
|
12582471 |
2002 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease: anesthetic management and results.
|
11133594 |
2001 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The central role of vascular endothelial growth factor (VEGF) in angiogenesis in health and disease makes it attractive both as a therapeutic target for anti-angiogenic drugs and as a pro-angiogenic cytokine for the treatment of ischaemic heart disease.
|
11166270 |
2001 |
Coronary Arteriosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Because hypoxia-inducible factor (HIF)-1alpha is a transcriptional activator of vascular endothelial growth factor (VEGF) and is critical for initiating angiogenic responses to hypoxia, we investigated the expression of HIF-1alpha and VEGF in specimens of human heart tissue to elucidate the molecular responses to myocardial ischemia in diabetic patients during unstable angina.
|
15331549 |
2004 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Catheter-based intracoronary vascular endothelial growth factor (VEGF) gene transfer is a potential treatment for coronary heart disease.
|
12742981 |
2003 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, VEGF microparticles and CoQ10 nanoparticles can be considered as promising strategies for managing MI.
|
23639291 |
2013 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recent experiments performed in this same porcine model of myocardial ischemia have shown that direct intramyocardial gene transfer of naked plasmid DNA encoding VEGF (phVEGF(165), the identical plasmid used in our previous animal and human clinical trials) can be safely and successfully achieved through a minimally invasive chest wall incision.
|
10426872 |
1999 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this brief review, the role of a prime angiogenic candidate, namely vascular endothelial growth factor (VEGF) and its homologues, in physiological and pathological angiogenesis will be discussed with particular attention to myocardial ischemia and heart failure.
|
10865845 |
2000 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Epicardial fat was clearly different from substernal fat because there was a far higher expression of haptoglobin, prostaglandin D(2) synthase, nerve growth factor beta, the soluble vascular endothelial growth factor receptor (FLT1), and alpha1 glycoprotein but not of inflammatory adipokines such as monocyte chemoattractant protein-1, interleukin (IL)-8, IL-1beta, tumor necrosis factor alpha, serum amyloid A, plasminogen activator inhibitor-1, or adiponectin despite underlying coronary atherosclerosis.
|
20116810 |
2010 |
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Vascular endothelial growth factor (VEGF) and its receptor KDR (kinase insert domain-containing receptor/fetal liver kinase-1, also called VEGFR2) play critical roles in angiogenesis and vascular repair, which are involved in the progress of coronary heart disease.
|
17707181 |
2007 |